These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 32291195)

  • 1. Atherogenic Dyslipidaemia 2019. Consensus document of the Atherogenic Dyslipidaemia Group of the Spanish Arteriosclerosis Society.
    Ascaso JF; Millán J; Hernández-Mijares A; Blasco M; Brea Á; Díaz Á; Pedro-Botet J; Pintó X;
    Clin Investig Arterioscler; 2020; 32(3):120-125. PubMed ID: 32291195
    [No Abstract]   [Full Text] [Related]  

  • 2. Consensus document on the management of the atherogenic dyslipidaemia of the Spanish Society of Arteriosclerosis.
    Ascaso JF; Millán J; Hernández-Mijares A; Blasco M; Brea Á; Díaz Á; Mantilla T; Pedro-Botet J; Pintó X;
    Clin Investig Arterioscler; 2017; 29(2):86-91. PubMed ID: 28185675
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Official document of the International Society of Atherosclerosis: general recommendations for treatment of dyslipidemia. Executive summary].
    ; Grundy SM; Arai H; Barter P; Bersot TP; Betteridge DJ; Carmena R; Cuevas A; Davidson MH; Genest J; Kesäniemi YA; Sadikot S; Santos RD; Susekov A; Sy R; Tokgozoglu L; Watts GF; Zhao D;
    Clin Investig Arterioscler; 2014; 26(1):33-7. PubMed ID: 24169377
    [No Abstract]   [Full Text] [Related]  

  • 4. Current ways of treating dyslipidemias to prevent atherosclerosis.
    Angelico F; Baratta F; Del Ben M
    Ther Apher Dial; 2013 Apr; 17(2):125-9. PubMed ID: 23551668
    [No Abstract]   [Full Text] [Related]  

  • 5. [The new 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk: comparison with the ESC/EAS recommendations for the management of dyslipidemias].
    Catapano AL; Averna M; Faggiano P; Novo S
    G Ital Cardiol (Rome); 2014 Jan; 15(1):19-20. PubMed ID: 24503730
    [No Abstract]   [Full Text] [Related]  

  • 6. Clinical implications of the metabolic syndrome.
    Ceska R
    Diab Vasc Dis Res; 2007 Sep; 4 Suppl 3():S2-4. PubMed ID: 17935057
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Management of inherited atherogenic dyslipidemias in children.
    Guardamagna O; Cagliero P; Abello F
    Ther Apher Dial; 2013 Apr; 17(2):150-61. PubMed ID: 23551671
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Atherogenic dyslipidemia and residual risk. State of the art in 2014].
    Millán Núñez-Cortés J; Pedro-Botet Montoya J; Pintó Sala X;
    Clin Investig Arterioscler; 2014; 26(6):287-92. PubMed ID: 25450326
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Triglycerides, HDL cholesterol and atherogenic dyslipidaemia in the 2019 European guidelines for the management of dyslipidaemias.
    Pedro-Botet J; Ascaso JF; Blasco M; Brea Á; Díaz Á; Hernández-Mijares A; Pintó X; Millán J;
    Clin Investig Arterioscler; 2020; 32(5):209-218. PubMed ID: 32037300
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Dyslipidaemia and vascular risk. A new evidence based review].
    Pallarés-Carratalá V; Pascual-Fuster V; Godoy-Rocatí D
    Semergen; 2015; 41(8):435-45. PubMed ID: 25559484
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Consensus document of an expert group from the Spanish Society of Arteriosclerosis (SEA) on the clinical use of nuclear magnetic resonance to assess lipoprotein metabolism (Liposcale®).
    Pintó X; Masana L; Civeira F; Real J; Ibarretxe D; Candas B; Puzo J; Díaz JL; Amigó N; Esteban M; Valdivielso P
    Clin Investig Arterioscler; 2020; 32(5):219-229. PubMed ID: 32798078
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of dyslipidaemia in childhood.
    Kusters DM; Vissers MN; Wiegman A; Kastelein JJ; Hutten BA
    Expert Opin Pharmacother; 2010 Apr; 11(5):739-53. PubMed ID: 20210683
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Practical recommendations for the management of cardiovascular risk associated with atherogenic dyslipidemia, with special attention to residual risk. Spanish adaptation of a European Consensus of Experts.
    Grupo de trabajo de Dislipemia Aterogénica de la Sociedad Española de Arteriosclerosis y Grupo Europeo de Expertos
    Clin Investig Arterioscler; 2017; 29(4):168-177. PubMed ID: 28433209
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The role of atherogenic dyslipidaemia in clinical practice guidelines].
    Pedro-Botet J; Mantilla-Morató T; Díaz-Rodríguez Á; Brea-Hernando Á; González-Santos P; Hernández-Mijares A; Pintó X; Millán Núñez-Cortés J
    Clin Investig Arterioscler; 2016; 28(2):65-70. PubMed ID: 26949069
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Atherogenic dyslipidemia.
    Hayden MR
    J Cardiometab Syndr; 2006; 1(3):166-7. PubMed ID: 17679821
    [No Abstract]   [Full Text] [Related]  

  • 16. [PCSK9 inhibitor use in high cardiovascular risk patients: an interventionalist's overview on efficacy, current recommendations and factual prescription].
    Masiero G; Franzone A; Silvestri T; Castiglioni B; Greco F; La Manna AG; Limbruno U; Longoni M; Marchese A; Mattesini A; Mauro C; Rigattieri S; Tarantino FF; Esposito G; Musumeci G; Tarantini G
    G Ital Cardiol (Rome); 2020 Apr; 21(4):264-270. PubMed ID: 32202557
    [No Abstract]   [Full Text] [Related]  

  • 17. The importance of dyslipidaemia in the pathogenesis of cardiovascular disease in people with diabetes.
    Gonna H; Ray KK
    Diabetes Obes Metab; 2019 Apr; 21 Suppl 1():6-16. PubMed ID: 31002453
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dyslipidaemia: Anti-PCSK9 vaccines to halt atherosclerosis.
    Ummarino D
    Nat Rev Cardiol; 2017 Aug; 14(8):442-443. PubMed ID: 28682322
    [No Abstract]   [Full Text] [Related]  

  • 19. Standardization of laboratory lipid profile assessment: A call for action with a special focus on the 2016 ESC/EAS dyslipidemia guidelines - Executive summary: A consensus endorsed by the Cardiovascular Risk and Prevention Group of the Portuguese Internal Medicine Society, the Portuguese Atherosclerosis Society, the Portuguese Society of Cardiology, the Portuguese Society of Laboratory Medicine, and the Portuguese Association of Clinical Chemistry.
    da Silva PM; Sequeira Duarte J; von Hafe P; Gil V; Nunes de Oliveira J; de Sousa G
    Rev Port Cardiol (Engl Ed); 2018 Apr; 37(4):279-283. PubMed ID: 29685846
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Atherogenic dyslipidemia: a multidisciplinary consensus panel].
    Foro Dislipidemia Aterogénica
    Clin Investig Arterioscler; 2013; 25(2):83-91. PubMed ID: 23747118
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.